College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Genome Med. 2023 Sep 1;15(1):65. doi: 10.1186/s13073-023-01220-4.
Breast cancer patients from the indigenous Arab population present much earlier than patients from Western countries and have traditionally been underrepresented in cancer genomics studies. The contribution of polygenic and Mendelian risk toward the earlier onset of breast cancer in the population remains elusive.
We performed low-pass whole genome sequencing (lpWGS) and whole-exome sequencing (WES) from 220 female breast cancer patients unselected for positive family history from the indigenous Arab population. Using publicly available resources, we imputed population-specific variants and calculated breast cancer burden-sensitive polygenic risk scores (PRS). Variant pathogenicity was also evaluated on exome variants with high coverage.
Variants imputed from lpWGS showed high concordance with paired exome (median dosage correlation: 0.9459, Interquartile range: 0.9410-0.9490). After adjusting the PRS to the Arab population, we found significant associations between PRS performance in risk prediction and first-degree relative breast cancer history prediction (Spearman rho=0.43, p = 0.03), where breast cancer patients in the top PRS decile are 5.53 (95% CI 1.76-17.97, p = 0.003) times more likely also to have a first-degree relative diagnosed with breast cancer compared to those in the middle deciles. In addition, we found evidence for the genetic liability threshold model of breast cancer where among patients with a family history of breast cancer, pathogenic rare variant carriers had significantly lower PRS than non-carriers (p = 0.0205, Mann-Whitney U test) while for non-carriers every standard deviation increase in PRS corresponded to 4.52 years (95% CI 8.88-0.17, p = 0.042) earlier age of presentation.
Overall, our study provides a framework to assess polygenic risk in an understudied population using lpWGS and identifies common variant risk as a factor independent of pathogenic variant carrier status for earlier age of onset of breast cancer among indigenous Arab breast cancer patients.
与来自西方国家的患者相比,来自阿拉伯本土的乳腺癌患者发病更早,且传统上他们在癌症基因组学研究中的代表性不足。人群中多基因和孟德尔风险对乳腺癌发病年龄较早的贡献仍不清楚。
我们对 220 名未选择阳性家族史的阿拉伯本土女性乳腺癌患者进行了低深度全基因组测序(lpWGS)和全外显子组测序(WES)。利用公开资源,我们对群体特异性变体进行了推断,并计算了乳腺癌负担敏感的多基因风险评分(PRS)。还对高覆盖度的外显子变体进行了变体致病性评估。
lpWGS 推断的变体与配对外显子高度一致(中位数剂量相关性:0.9459,四分位距:0.9410-0.9490)。在将 PRS 调整为阿拉伯人群后,我们发现 PRS 在风险预测和一级亲属乳腺癌病史预测中的表现之间存在显著关联(Spearman rho=0.43,p=0.03),PRS 最高十分位数的乳腺癌患者中,一级亲属诊断为乳腺癌的患者比中间十分位数的患者多 5.53 倍(95% CI 1.76-17.97,p=0.003)。此外,我们发现乳腺癌的遗传易感性阈值模型存在证据,即在有乳腺癌家族史的患者中,致病性罕见变异携带者的 PRS 明显低于非携带者(p=0.0205,Mann-Whitney U 检验),而非携带者的 PRS 每增加一个标准差,其发病年龄就会提前 4.52 岁(95% CI 8.88-0.17,p=0.042)。
总体而言,我们的研究提供了一个使用 lpWGS 评估未充分研究人群多基因风险的框架,并确定了常见变异风险是阿拉伯本土乳腺癌患者发病年龄较早的独立于致病性变异携带者状态的因素。